The Quantellect read.As of Nov 19, 2026, 8 active firms cover Palisade Bio Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $5.00 to $25.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $9.63 sits 912% above the current $0.95. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.63
+911.9% upside
Average target across 8 active firms as of Nov 19, 2026 vs $0.95 current
Highest Target$25.00
Average Target$9.63
Lowest Target$5.00
Detailed analyst forecasts for PALI
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate PALI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PALI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 4 analysts
Next period, 4 analysts expect Palisade Bio Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus — a year earlier. Full-year consensus is $-0.24, growing to $-0.33 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $444.4K, rising to $0 next year.
Top analysts covering Palisade Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PALI.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$7.00+635.9% to target
Overall win rate
33%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$25.00+2528.3% to target
Overall win rate
30%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #404
Buy
$8.00+741.0% to target
Overall win rate
35%
+ Follow
#4
NR
Naz Rahman
Maxim Group · Rank #578
Buy
$8.00+741.0% to target
Overall win rate
27%
+ Follow
#5
Alex Thompson CFA
Stifel Nicolaus
Buy
$5.00+425.7% to target
Coverage
—
+ Follow
PALI stock forecast FAQ
What is PALI's average 12-month price target?+
The 8 active firms with a live target average $9.63 for Palisade Bio Inc over the next 12 months, ranging from a $25.00 high to a $5.00 low, as of Nov 19, 2026.
Is PALI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PALI?+
The Street-high target is $25.00 (Piper Sandler), and the Street-low is $5.00 (Stifel). The average of all 8 active-firm targets is $9.63.
How many active Wall Street firms cover PALI?+
8 active firms have a recognized rating on Palisade Bio Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PALI?+
Among analysts who currently cover PALI, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #305). Their current call is Buy with a $7.00 target.
What is Palisade Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 4 analysts. Full-year EPS is projected at $-0.24, rising to $-0.33 the following year.
How much revenue is Palisade Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $444.4K, growing to $0 next year.
Have analysts been upgrading or downgrading PALI lately?+
As of Nov 19, 2026, 8 of 8 active firms rate PALI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PALI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.